Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study in: Endocrine-Related Cancer Volume 23 Issue 3 (2016)
Estimates of PFS among patients who received lanreotide depot (120 mg)... | Download Scientific Diagram
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors | NEJM
Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment (Elect): A Randomized, Double-Blind
CLINICAL STUDY RESULTS
![PDF] Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a82b998becc9ea2f23aed89d6c17821920c6b73b/4-Figure1-1.png "PDF] Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study | Semantic Scholar")
PDF] Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study | Semantic Scholar
Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot ( lanreotide)
Cancers | Free Full-Text | Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study
PFS in GEP-NETs Patients | Somatuline® Depot 120mg Injection | HCP
Clinical Trial: Phase II CLARINET FORTE Somatuline Autogel (Lanreotide) increased dosing frequency - Ronny Allan - Living with Neuroendocrine Cancer
Treatment of neuroendocrine tumors: new recommendations based on the CLARINET study
Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study | SpringerLink
![PDF] Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a82b998becc9ea2f23aed89d6c17821920c6b73b/7-Figure2-1.png "PDF] Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study | Semantic Scholar")
PDF] Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study | Semantic Scholar
Essential Concepts in the Use of Somatostatin Analogues in Patients with Neuroendocrine Tumors (Transcript)
PFS for lanreotide autogel/depot from the CLARINET core study and the... | Download Scientific Diagram
Cancers | Free Full-Text | Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study
Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study | SpringerLink
Lanreotide Autogel (LAN) 120 mg Every 14 Days in Progressive Pancreatic Neuroendocrine Tumors (panNETs): CLARINET FORTE Study
Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results - ScienceDirect
![CLARINET FORTE study design [5]. ECOG PS Eastern Cooperative Oncology... | Download Scientific Diagram](https://www.researchgate.net/publication/360331878/figure/fig1/AS:1164524258365440@1654655627672/CLARINET-FORTE-study-design-5-ECOG-PS-Eastern-Cooperative-Oncology-Group-Performance.png "CLARINET FORTE study design [5]. ECOG PS Eastern Cooperative Oncology... | Download Scientific Diagram")
CLARINET FORTE study design [5]. ECOG PS Eastern Cooperative Oncology... | Download Scientific Diagram
The Cost-Effectiveness of Initial vs. Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors in
Reassessing the Role of Somatostatin Analogs in the Treatment of NETs (Transcript)
GTG on Twitter: "Pavel et al, ph 2 CLARINET FORTE trial. High dose lanreotide in progressive GEP-NETs: - mPFS 5.6 mo in PanNET cohort - mPFS 8.3 mo in migut cohort -
Frontiers | Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus
![PDF] Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a82b998becc9ea2f23aed89d6c17821920c6b73b/6-Table2-1.png "PDF] Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study | Semantic Scholar")